Teva, Glenmark to pay $255 million to resolve DOJ price-fixing claims
Teva Pharmaceuticals and Glenmark Pharmaceuticals reached deferred prosecution agreements with the Department of Justice to resolve antitrust claims over a generic drug price-fixing cartel....
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch